IMS IMS Health recently released its World Review 2015. The new general manager of North Latin America shares the company’s assessment on the performance of the Mexican pharmaceutical market for 2014, what trends are shaping the industry as well as the moderate, yet positive outlook for 2015. How would you assess…
consulting IMS’s top consultant in Turkey discusses the common pattern that companies in Turkey have and must follow to adapt to today’s market, and the importance of heeding market signals, such as the growing specialty drugs segment and shift towards the hospital sales channel. What changes have you seen in the…
doing business The president and founder of Knobloch Information Group, the leading supplier of market data to the pharmaceutical industry in Mexico, provides an in-depth overlook about the most important changes that are reshaping the Mexican pharmaceutical market. Knobloch Information Group is the leading supplier of market data to the pharmaceutical industry…
IMS IMS in Malaysia is possibly the first company to have signed a Memorandum of Understanding with the government for data provision. IMS Health’s general manager introduces this landmark and also shares the opportunities present for pharma companies to invest in Malaysia. IMS is now providing data for the…
Generics Al Z. Castro, General Manager of IMS Health Philippines, speaks about the ongoing challenges of bringing about awareness and acceptance of generics medicine to the local population, how this will affect IMS Health, and what their strategy is going forward over the next five years. IMS Health has previously classified…
Generics Tom Rönnlund discusses the current state of the pharmaceutical industry in the Nordics in this time of austerity, and offers opinions on reference pricing and cooperation in the region. How have the markets in Denmark and Sweden evolves over the past five years, since the financial crisis started and austerity…
government relations Mike Brogan, before taking up the mantle of President at IMS was VP of Business Integration at IMS for a year. Today, he talks about the difficulties he has come up against since becoming President, especially in government relations and investment. He also offers insights on the future of marketing…
IMS Health Ireland Mr. Egan, what path led you to IMS Health? My original background is in science—I received a PhD in medical microbiology, and worked for some time as a post-doctoral researcher for a Swedish biotech company that was contracting research services here in Ireland. I have since hung up my lab…
IMSS (Mexican Institute of Social Security) IMSS is a central pillar in the Mexican healthcare system, covering all Mexicans working for the declared formal private sector. How do you assess the quality of the healthcare that is provided by IMSS? To assess the efficiency of our services, it is key to look at the amount of…
IMS Health Belgium Looking at your background, we see that you have been with IMS for over 12 years. What defines your loyalty to the company? What appeals most to you about IMS? My loyalty to IMS Health lies in the opportunities I have been presented during all these years. Although I have…
IMS Health Brazil We know the raw data already in the Brazilian market and the number changes since our last visit in 2007 – but how would you interpret these changes into a coherent story explaining the evolution since that time in the country’s pharmaceutical history? The one major factor influencing country growth…
IMS Health Turkey Before we start with the interview I noticed that previously you were in charge of other regions aside from turkey. Is that still the case? If not why did IMS decide to separate Turkey from these regions ? Every third or fourth year, according to the growth of each country…
See our Cookie Privacy Policy Here